Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from Qiagen ( (QGEN) ).
QIAGEN has disclosed that the Dutch financial markets regulator AFM notified the company of a substantial shareholding in QIAGEN held by DWS Investment GmbH, following a transaction dated January 22, 2026. DWS now holds 3,505,071 ordinary shares in QIAGEN, corresponding to a capital interest of 1.69% and 3.02% of the voting rights, a stake that may influence shareholder dynamics and governance considerations but does not alter control of the company.
The most recent analyst rating on (QGEN) stock is a Buy with a $61.00 price target. To see the full list of analyst forecasts on Qiagen stock, see the QGEN Stock Forecast page.
More about Qiagen
QIAGEN N.V., based in Venlo, Netherlands, is a life sciences and diagnostics company whose shares are listed on multiple European exchanges including Frankfurt as well as on the NYSE and Swiss markets, giving it broad access to international capital markets and a diverse investor base.
Average Trading Volume: 1,827,255
Technical Sentiment Signal: Strong Buy
Current Market Cap: $11.17B
Find detailed analytics on QGEN stock on TipRanks’ Stock Analysis page.